Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Amneal Pharmaceuticals's enterprise value was $9.55B on Nov 11, 2026, against $6.38B a year earlier. Over the last 5 years it ranged from $2.64B to $9.55B, with a median of $3.80B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $9.55B | +49.1% |
| 2025 | Dec 31, 2025 | $6.41B | +38.1% |
| 2024 | Dec 31, 2024 | $4.64B | +42.9% |
| 2023 | Dec 29, 2023 | $3.25B | +18.2% |
| 2022 | Dec 30, 2022 | $2.75B | -13.3% |
| 2021 | Dec 31, 2021 | $3.17B | -1.6% |
| 2020 | Dec 31, 2020 | $3.22B | +0.0% |
| 2019 | Dec 31, 2019 | $3.22B | -17.6% |
| 2018 | Dec 31, 2018 | $3.91B | – |
See a number that looks wrong?